Search results
Results from the WOW.Com Content Network
Dengue vaccine is a vaccine used to prevent dengue fever in humans. [9] Development of dengue vaccines began in the 1920s, but was hindered by the need to create immunity against all four dengue serotypes. [10] As of 2023, there are two commercially available vaccines, sold under the brand names Dengvaxia and Qdenga. [11] [12]
Dengue is spread by several species of female mosquitoes of the Aedes genus, principally Aedes aegypti. [1] Infection can be prevented by mosquito elimination and the prevention of bites. [12] Two types of dengue vaccine have been approved and are commercially available.
In May 2024, TAK-003 became the second dengue vaccine to be prequalified by the World Health Organization (WHO). [47] This live-attenuated vaccine, developed by Takeda is similar to the Dengvaxia vaccine in the fact that it contains a weakened version of the four variants of dengue virus. The difference between the two vaccines is the TAK-003 ...
Meanwhile, headlines proclaiming that malaria could be eradicated within a decade are generating excitement after the development of an affordable vaccine against the devastating disease that ...
Dengue fever typically carries a mortality rate of less than 1% if it is detected early and treated properly. If left untreated, the mortality rate can be as high as 20%, the CDC said. Show comments
This vaccine is the first to meet the World Health Organization's Malaria Vaccine Technology Roadmap goal of a vaccine with at least 75% efficacy. [144] Germany-based BioNTECH SE is developing an mRNA-based malaria vaccine BN165 [145] which has recently initiated a Phase 1 study [clinicaltrials.gov identifier: NCT05581641] in December 2022. The ...
Takeda's vaccine, given in two doses over a three-month interval, protects against four serotypes of the dengue virus. It was cleared by WHO for use in children aged 6 to 16 in areas with high ...
The most effective malaria vaccine is the R21/Matrix-M, with a 77% efficacy rate shown in initial trials and significantly higher antibody levels than with the RTS,S vaccine. It is the first vaccine that meets the World Health Organization's (WHO) goal of a malaria vaccine with at least 75% efficacy, [6] [7] and only the second malaria vaccine ...